Influenza Diagnostics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Influenza Diagnostics Market Trends and Insights

Rising Prevalence & Severity of Seasonal and Zoonotic Influenza Outbreaks

A resurgence in seasonal influenza activity has intensified global diagnostic demand, with the CDC logging 39,053 laboratory-confirmed hospitalizations during the 2024-2025 season, the highest rate since 2010-2011.^{[1]Centers for Disease Control and Prevention, “Weekly Flu Season Update,” cdc.gov}Concurrently, highly pathogenic H5N1 outbreaks generated 38 human cases in California among dairy workers, prompting expanded livestock surveillance. New kits, such as Singapore’s Steadfast assay, differentiate highly and low pathogenic strains within three hours, enhancing outbreak response. These events push health systems to retain emergency-level testing capacity year-round, sustaining procurement of high-accuracy molecular platforms.

Growing Adoption of Rapid Point-of-Care Tests in Outpatient Settings

Hospital studies from the University of Southampton showed that POC influenza testing cuts result time to under one hour, enabling faster antiviral initiation and shorter patient stays. Platforms now include molecular options like Abbott’s ID NOW, which returns influenza A/B results in 13 minutes with 96.3% sensitivity. AI-enhanced readers further reduce interpretation time to two minutes.^{[2]Baozhang Li, “TIMESAVER: Rapid Deep-Learning Interpretation of Lateral-Flow Assays,” Nature Communications, nature.com} Lower transport costs and same-visit treatment support economic arguments for widespread POC deployment in clinics and retail health sites.

Government-Funded Surveillance Programs & Pandemic-Preparedness Budgets

Post-COVID lessons spurred higher allocations, with the U.S. Department of Health and Human Services earmarking USD 172 million for influenza preparedness in FY 2025. The CDC now partners with commercial labs such as Quest Diagnostics and Labcorp to expand avian influenza testing capacity. Meanwhile, WHO achieved full national influenza center coverage across 11 South-East Asian countries in 2024, a milestone that elevates baseline demand for standardized diagnostic kits. These programs stabilize procurement cycles and set performance benchmarks that steer private-sector R&D.

AI-Powered Result-Interpretation Software Boosting Molecular Workflow Throughput

Machine-learning pipelines now classify viral sequences and flag mutations faster than manual processes, increasing laboratory throughput without new hardware.^{[3]Hannah R. Meredith, “Machine-Learning Pipeline Accelerates Virus Detection and SNP Discovery,” PubMed Central, ncbi.nlm.nih.gov}BugSeq’s collaboration with BARDA brings AI-driven reporting to clinical metagenomics, underpinning pathogen-agnostic surveillance. TIMESAVER, a deep-learning algorithm, lifted the sensitivity of lateral-flow assays for influenza A/B to 93.8% while slashing read time to two minutes. Laboratories deploying such tools improve quality-control consistency and can flex capacity during seasonal peaks. 

Variable Sensitivity & False-Negative Rate of RIDTs

Many RIDTs miss early infections when viral load is low; studies place false-negative rates above 30% for certain commercial kits. The Panbio COVID-19/Flu A&B panel delivered only 80.8% sensitivity for influenza. WHO’s 2024 guidance now recommends nucleic-acid tests for severe or high-risk cases. Clinics have introduced confirmatory PCR workflows that erase the speed advantage of RIDTs, curbing segment expansion.

High Capital & Running Cost of Molecular Diagnostic Platforms

Comprehensive systems like Roche’s Cobas 6800 require significant capital plus service contracts beyond many mid-size hospitals’ budgets. Reagents, maintenance, and skilled labor keep operating expenses elevated; supply-chain shocks further lift logistics outlays, which reached nearly 20% of revenue for device makers in 2024. In lower-income markets, limited reimbursement for syndromic panels slows adoption despite clinical advantages.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Test Type: CRISPR Innovation Challenges Traditional Dominance

Rapid formats remained dominant with a 41.10% revenue share, yet the influenza diagnostics market is repositioning as clinicians prioritize sensitivity and multiplexing. CRISPR assays show 9.28% CAGR by 2031, led by the Broad Institute’s SHINE test that discriminates subtypes in 15 minutes. Molecular panels that bundle influenza A/B, RSV, and SARS-CoV-2 deliver operational efficiency for emergency departments. The influenza diagnostics market size for CRISPR platforms is forecast to expand fastest among all modalities, driven by simplified workflows and shrinking instrument footprints. Direct fluorescent antibody and viral culture testing continue to serve research niches where strain typing or antiviral susceptibility is required, but they no longer influence mainstream purchasing decisions.

Molecular diagnostics, including RT-PCR and isothermal formats, see accelerated uptake as AI tools streamline result interpretation. Multiplex CRISPR-Cas13a strips achieved 100% concordance with RT-qPCR while removing amplification steps. Hospitals prefer syndromic panels that differentiate overlapping respiratory symptoms within a single sample, whereas retail clinics adopt CLIA-waived molecular cartridges for rapid walk-in encounters. This convergence of accuracy and speed positions molecular solutions to erode RIDT leadership as capital barriers abate. 

By End User: Hospital Consolidation Versus POC Expansion

Hospitals and clinical laboratories generated 41.85% of 2025 revenue by leveraging high-throughput instruments and in-house microbiology expertise. Consolidation among health systems concentrates purchasing power, allowing bulk reagent contracts that stabilize supply. Point-of-care venues, however, exhibit the highest 9.12% CAGR as physicians require immediate answers for treatment during a single visit. The influenza diagnostics market share held by pharmacies and urgent-care centers continues to climb as retailers like CVS deploy 3-in-1 combo tests across 1,600 sites.

Independent diagnostic laboratories maintain relevance by servicing outpatient clinics and specialist practices, but face referral declines where hospitals move tests in-house. Home testing forms an emerging sub-segment after the FDA cleared the first OTC combo flu/COVID assay in 2024. Across all settings, the influenza diagnostics industry leverages telehealth connections to relay results directly into electronic health records, supporting antiviral e-prescriptions without extra clinic visits. Source: https://www.mordorintelligence.com/industry-reports/global-influenza-diagnostics-market

Geography Analysis

North America’s leadership stems from comprehensive surveillance systems and mature reimbursement models. The CDC coordinates eight regional surveillance hubs spanning 125 countries, yet maintains its largest testing footprint domestically. The influenza diagnostics market size in North America benefits from Thermo Fisher Scientific’s USD 2 billion investment to expand domestic manufacturing, aimed at insulating supply chains. Retail pharmacies integrate CLIA-waived molecular cartridges for same-visit care, while health insurers increasingly reimburse home-collection kits, broadening consumer access.

Asia Pacific posts the fastest 7.78% CAGR owing to rapid laboratory build-outs and government funding. WHO’s milestone of 11 fully operational national influenza centers across South-East Asia evidences this progress. Japan updated quality-management regulations to align with ISO 13485:2016, smoothing approval pathways for foreign assay developers. China and India funnel vaccine-related mRNA investments into diagnostics, fostering locally made CRISPR cartridges for regional distribution.

Europe remains influential through the In Vitro Diagnostic Regulation (IVDR), which raises conformity-assessment requirements from 15% to nearly 90% of assays. Transition extensions granted in 2024 prevent immediate supply shortages but raise compliance costs that could shift R&D to fewer, higher-value tests. Middle East & Africa and South America pursue capacity growth via multilateral aid and public-private partnerships; the OECD urges diversified sourcing to mitigate logistic shocks experienced during the pandemic. This uneven readiness shapes divergent adoption curves, yet shared emphasis on respiratory surveillance sustains global demand for robust assays. Source: https://www.mordorintelligence.com/industry-reports/global-influenza-diagnostics-market

Regulatory Landscape

Influenza diagnostics are regulated as in vitro diagnostics, with pathway and evidence requirements that vary by risk class and intended use. In the United States, many influenza tests fall under FDA Class II frameworks with 510(k) premarket review. Special controls for influenza virus antigen detection test systems include ongoing analytical reactivity expectations against contemporary strains, with annual reactivity testing and time-bound testing following FDA notification when characterized samples become available. FDA also maintains device classifications and guidance for influenza diagnostic tests, including reagents intended for detection of specific novel influenza viruses.

In Europe, implementation of the In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR) raises conformity-assessment and performance evaluation requirements, particularly for higher-risk assays. For Class D IVDs, the European system incorporates expert input through mechanisms such as the Performance Evaluation Consultation Procedure (PECP) and expert panel views coordinated via EMA processes. Globally, WHO guidance and standard methods under the Global Influenza Surveillance and Response System (GISRS) influence laboratory practices and quality benchmarks, including recommended protocols for detection, characterization, and surveillance of influenza viruses.

Value Chain Analysis

The influenza diagnostics value chain covers upstream suppliers of critical inputs, including antibodies, enzymes, primers/probes, synthetic oligonucleotides, plastics, and microfluidic components. It also includes assay and instrument manufacturers, such as those offering RIDTs, RT-PCR and other molecular platforms, and multiplex panels, plus regulated packaging and cold-chain logistics for time- and temperature-sensitive reagents. Midstream activities include validation, quality systems, and regulatory submissions, such as FDA 510(k) clearances, followed by downstream commercialization through direct sales and specialized distributors serving hospitals, clinical laboratories, and point-of-care (POC) sites such as urgent care and retail clinics.

Distribution partnerships and public-sector procurement influence go-to-market speed and installed base utilization. For example, Quest Diagnostics received CDC contracts (October 2024) supporting testing readiness for H5 avian influenza and other threats, reinforcing demand for equipment and reagents and strengthening the commercial lab role in outbreak-linked testing capacity. In the US hospital channel, the January 2026 exclusive distribution agreement between Fisher Scientific (Thermo Fisher Scientific) and DiaSorin for the LIAISON NES molecular POC platform highlights how large distributors can accelerate adoption of CLIA-waived and 510(k)-cleared molecular systems, while also tightening competition for shelf space and service coverage.

Market Opportunities and Future Outlook

An opportunity area is ultra-rapid, CLIA-waived molecular testing that enables multiplex respiratory differentiation in near-patient settings without compromising sensitivity. FDA actions in 2026 support this direction. Autonomous Medical Devices Incorporated (AMDI) received 510(k) clearance and a CLIA waiver (June 2026) for a multiplex RT-PCR mini respiratory panel that reports RSV, influenza A, influenza B, and SARS-CoV-2 in under 10 minutes. Baebies received FDA 510(k) clearance and a CLIA waiver (March 2026) for a triplex respiratory test on its Finder system, positioning multifunctional POC devices that pair molecular testing with other modalities as an adoption lever for decentralized care sites.

A second whitespace involves standardized, surveillance-aligned molecular testing that can be deployed across networks while maintaining comparable performance and reporting, supported by public-health guidance and lab quality programs. CDC resources on influenza and influenza/SARS-CoV-2 multiplex assays, along with WHO laboratory manuals and GISRS methods, keep RT-PCR and validated multiplex workflows central to both seasonal and novel influenza response. Commercial traction for integrated respiratory panels is reinforced by continued 510(k) clearances, including DiaSorin LIAISON NES FLU A/B, RSV and COVID-19 (December 2025) and Nano-Ditech dual influenza and COVID-19 antigen test (June 2025), which helps expand the installed base that laboratories and POC operators can use for year-round respiratory testing pathways.